Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can someone post the latest PR on the "Breaking Stock-Related News" board? I don't have that privilege.
Schwab still showing 37 - I wanna see green!
Schwab now showing .0037. It was .0038 at 4:00. What happened here?
104.1 KRBE in Houston talking about Trek Funerals right now. They asked what your special request would be for your funeral. The phone number is 713-390-KRBE. Call
You forgot to mention the Klingon language.
http://www.kli.org/
I just googled "star trek fans" and got a ton of websites loaded with trekkie fans. Let's all get on there and spread the word to these faithful followers. I think they would be ecstatic about this news and it could spread like wild fire.
I'm thinking Hollywood will be all over this one. There's a new movie (#11) scheduled to be released December 2008 and they're looking at Russell Crowe to play a bad guy.
Sorry if this has already been mentioned - I can't keep up with all the messages on this board.
CytoCore e2 Collector Compliant for the CE Mark
Wednesday August 8, 7:00 am ET
Cervical Cell Collection Device Qualified to Sell in Europe
CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR.OB - News), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced that it has completed the process of demonstrating conformity of the e2 Collector(TM) cervical cell collection device to the requirements of the Medical Device Directive for sales into the European Union.
ADVERTISEMENT
"We are pleased to have accomplished this significant objective. Demonstrating conformity to the essential requirements of the Medical Device Directive and, as a consequence, being able to affix the 'CE Mark' to the product is THE major milestone for selling the Collector into the European Union," said CytoCore's president, Dick Domanik. "In addition, the CE Mark is becoming increasingly important for entry into other countries. We are in the process of formally registering the e2 Collector with the individual countries as designated by our distribution partners. We are now ready to finalize certain initial distribution arrangements covering several European countries."
About CytoCore Inc.
NEWS - Final Three Sites Join CytoCore's e2 Collector Trial
Monday July 30, 4:09 pm ET
Three Additional University Sites Begin Participating in Ongoing Clinical Trial for Modified Device
CHICAGO--(BUSINESS WIRE)--CytoCore Inc. (OTCBB:CYCR - News), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced that Baylor University, University of Pittsburgh and University of Cincinnati are beginning to participate as new sites in CytoCore's current e2 Collector(TM) clinical trial. The current collector utilizes the same technology as previous versions. The improvement is "push button" convenience speeding the test and eliminating user caused sampling errors.
ADVERTISEMENT
"We are pleased to add these new sites to our on-going Collector Trial," said CytoCore's CEO Dr. Floyd Taub. "We now have the full group of seven locations participating in this trial. This trial is expected to confirm and expand previous data on adequacy, sensitivity and specificity of CytoCore's unique collector. While very sophisticated on the inside the collector is faster and easier to use than any on the market today. This study is six times larger than the one the FDA reviewed prior to the 510(k) approval."
Baylor University: http://www.baylor.edu/
University of Pittsburgh: http://www.medschool.pitt.edu/
University of Cincinnati: http://www.med.uc.edu/
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
I still only see the same 3 pictures I was talking about earlier. Nothing gory here. Maybe I'm just desensitized.
What are you guys talking about? I only see three pictures showing a portion of a lung that barely show anything. Am I not looking in the right place? If these are the pictures you are referring to then you've got to be kidding. What is so gross about them?
CSMG Technologies, Inc. Announces Ukraine Tissue Welding Patent Issued
Tuesday July 10, 10:00 am ET
CORPUS CHRISTI, Texas--(BUSINESS WIRE)--CSMG Technologies, Inc., (OTC Bulletin Board: CTUM - News) a technology management company, announced today the company has received a patent from Ukraine for "Method For Welding of Biological Tissue, Control Method For Welding Tissue (variants) and Apparatus For Biological Tissue Welding (variants)." This approval follows the U.S. patent approval. The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, Canadian and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.
ADVERTISEMENT
CSMG owns the technology and exclusive world rights to the live tissue bonding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology.
About CSMG Technologies, Inc.
CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG is focused on two primary subsidiaries, Live Tissue Connect, Inc. and landfill gas processing.
For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com
Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to http://www.ctum.com/contact_information.html and fill-in information.
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
Press Release Source: CytoCore Inc.
Gorodeski Presents Research on P2X7 for Treatment of Cancer at Purine and Pyrimidine Symposium in Chicago
Tuesday June 26, 11:52 am ET
CHICAGO--(BUSINESS WIRE)--Today Dr. George Gorodeski, Chief Scientist at CytoCore (OTCBB: CYCR - News), will present new aspects of his pioneering research at the 12th International Symposium on Purine and Pyrimidine Metabolism in Man, held at the InterContinental Hotel in Chicago.
ADVERTISEMENT
At the Symposium, sponsored by the Purine and Pyrimidine Society, Dr. Gorodeski will discuss the epigenetic control of P2X7 receptor gene expression by hyper-methylation and its implications for cancer therapeutics and prevention.
Dr. Gorodeski's presentation will cover the physiological and patho-biological roles of P2X7 in uterine epithelial cancer development; the role of hyper-methylation of the P2X7 gene as it relates to P2X7 mRNA expression; the post-transcriptional enhancement of P2X7 expression by compounds that promote de-methylation; and the therapeutic and cancer prevention potential of treatments based upon up-regulation of P2X7-mediated apoptosis.
About the Conference
http://www.ppsociety.org/symposium/pp07.php
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com
Dr. Gorodeski, MD, PhD, Professor of Reproductive Biology, Oncology and Physiology and Bio-physics at Case Western Reserve University and a faculty member at University Hospital Case Medical Center of Cleveland is director of the Medical Advisory Board and Chief Scientist at CytoCore Inc., the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers.
Dr. Gorodeski has a significant financial interest in this research consisting of equity and fees as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention is licensed to CytoCore could generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland, and for CASE University.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Ahhhhh! I finally got my PRVBwealth fix.
Missed ya,
Diana
Viva World Trade Signs Exclusive Deal to Distribute Vodka Mudshake in Mexico
Wednesday May 30, 10:15 am ET
PUERTO VALLARTA, MEXICO--(MARKET WIRE)--May 30, 2007 -- Viva World Trade, Inc. (Other OTC:VVWT.PK - News) and its Mexican subsidiary, Canmex Imports (the "Company," "Viva" or "Canmex"), an importer and distributor of premium alcoholic and non-alcoholic beverages in Mexico, are pleased to announce that the Company has signed an exclusive Agreement to distribute the popular Vodka Mudshake brand family in Mexico.
ADVERTISEMENT
The Vodka Mudshake brand is a premium Ready-to-Drink (RTD) alcoholic beverage produced by Independent Distillers Group in the United Kingdom and sold across Europe, Asia, New Zealand, and Australia.
Founded in 1987, Independent Distillers Group is a global manufacturer and distributor of alcoholic beverages. The Company's core business is its own RTD brands. Independent Distillers also produces a selection of beer, wine and spirits under its own brands, and distributes licensed brands in some markets. The Company was recently purchased by private equity firms for NZ$1.3 billion (US$945 million).
The Vodka Mudshake product is a unique blend of vodka and whole milk. A technological breakthrough in manufacturing and a specialized production process guarantees Vodka Mudshakes an unrefrigerated shelf life of 24 months. Vodka Mudshakes are available in seven delicious flavours -- Chocolate, Vanilla, Caramel, Honeycomb, Strawberry, Mint, and Banana.
"There has been enormous growth in the Ready-to-Drink alcoholic beverage segment over the last decade and Independent Distillers is definitely a market innovator. Their proprietary production process, which allows for extended unrefrigerated shelf life, makes the Vodka Mudshake the ideal milk based RTD for the Mexico marketplace," said Neil Mikkelsen, President & CEO.
Further information regarding the Company's current import and distribution business and potential sub-distribution agreements for Vodka Mudshake will be made available in forthcoming press releases.
About Viva World Trade, Inc.
Viva World Trade, Inc. is an importer and distributor of premium alcoholic and non-alcoholic beverages in Mexico. Viva and its Mexican subsidiary, Canmex Imports, are the exclusive importer and national distributor of the "mike's hard lemonade" brand family. "mike's hard lemonade" is one of North America's favorite and most successful flavored alcoholic beverages. The Company is also an authorized vendor and distributor for ROCKSTAR Energy Beverages. Viva World Trade, Inc. shares are traded over-the-counter on the Pink Sheets -- Trading Symbol: VVWT.
Disclaimer: Portions of this press release include "forward-looking statements," which may be understood as any statement other than a statement of historical fact. Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from management's expectations and projections expressed in this press release.
Contact:
For further information, contact:
Mercantile Ascendency, Inc.
Thomas Collins
Investor Relations
Tel: (214) 461-3500
Email: tcollins@mercantileascendency.com
Viva World Trade, Inc.
Neil Mikkelsen
President & CEO
Tel: (52) 322-209-0837
Email: contacto@canmeximports.com
To learn more about Viva World Trade, Inc., visit http://www.vivaworldtrade.com
Market News First
Angela Junell
214-461-3411
ajunell@MN1.com
--------------------------------------------------------------------------------
Source: Viva World Trade, Inc.
Press Release Source: Viva World Trade, Inc.
Viva World Trade Brewing up Business With Local UNO Beer
Friday May 11, 3:30 pm ET
PUERTO VALLARTA, MEXICO--(MARKET WIRE)--May 11, 2007 -- Viva World Trade, Inc. (Other OTC:VVWT.PK - News) and its Mexican subsidiary Canmex Imports (the "Company," "Viva" or "Canmex"), an importer and distributor of premium alcoholic and non-alcoholic beverages in Mexico, are pleased to provide this corporate update to shareholders regarding its recent business developments.
ADVERTISEMENT
Through an exclusive agreement with Kosako Brewery (Mexico), the Company has completed their unique beer formulations of lager, amber, and dark brews under the retail trademark of "Local UNO." The development of Local UNO brand beers will position the Company to profit from the rapidly growing global demand for Mexican brews.
Worldwide demand for Mexican beer has never been higher. In the U.S., Mexican beer leads all other imports by a wide margin, accounting for over 35% of the U.S. import market last year. Mexican beer has also seen its popularity and demand grow across Europe and Asia.
The Company has also completed extensive renovations at their new, unique concept sales, promotion, and corporate headquarters. Located on the exclusive Puerto Vallarta marina boardwalk, the new headquarters accommodate expanded corporate offices, a redesigned indoor showroom and sales center, and the Company's flagship outdoor sales, marketing and promotions platform, the "Local UNO Brew Pub."
It is expected that Local UNO Lager Beer will be available in keg format and test marketed with retail consumers and wholesale/distribution representatives at the Local UNO Brew Pub within the next few weeks.
"The completion of our new corporate headquarters, the opening of the Local UNO Brew Pub, and the finalizing of our unique Local UNO beer formulations with Kosako's brewmaster are significant milestones for the Company. Global demand and distributor interest in Mexican beer has grown significantly and our plans, subject to securing financing, are to take advantage of this growing trend," said Neil Mikkelsen, President & CEO.
About Viva World Trade, Inc.
Viva World Trade, Inc. is an importer and distributor of premium alcoholic and non-alcoholic beverages in Mexico. Viva and its Mexican subsidiary Canmex Imports are the exclusive importer and national distributor of the "mike's hard lemonade" brand family. "mike's hard lemonade" is one of North America's favorite and most successful flavored alcoholic beverages. The Company is also an authorized vendor and distributor for ROCKSTAR Energy Beverages. The ROCKSTAR brand family is a leader in the multi-billion dollar energy drink market. Viva World Trade, Inc. shares are traded over-the-counter on the Pink Sheets -- Trading Symbol: VVWT.
Disclaimer: Portions of this press release include "forward-looking statements," which may be understood as any statement other than a statement of historical fact. Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from management's expectations and projections expressed in this press release.
Contact:
For further information, contact:
Mercantile Ascendency, Inc.
Thomas Collins
Investor Relations
Tel: (214) 461-3500
Email: tcollins@mercantileascendency.com
Viva World Trade, Inc.
Neil Mikkelsen
President & CEO
Tel: (52) 322-209-0837
Email: contacto@canmeximports.com
To learn more about Viva World Trade, Inc., visit http://www.vivaworldtrade.com
Market News First
Angela Junell
214-461-3411
ajunell@MN1.com
--------------------------------------------------------------------------------
Source: Viva World Trade, Inc.
Press Release Source: CytoCore Inc.
Dr. George Gorodeski to Speak at NYSSA Medical Equipment & Supplies Conference
Wednesday May 9, 9:31 am ET
CytoCore Chief Scientist to Discuss Advances in Reproductive Cancer Detection and Treatment
CHICAGO--(BUSINESS WIRE)--Dr. George Gorodeski, director of the Medical Advisory Board and Chief Scientist at CytoCore Inc. (OTCBB:CYCR - News), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, will present at the New York Society of Security Analysts (NYSSA) Medical Equipment and Supplies Conference in New York City on Tuesday, June 12, 2007.
ADVERTISEMENT
Dr. Gorodeski, Professor of Reproductive Biology, Oncology, and Physiology and Bio-physics at Case Western Reserve University and a faculty member at University Hospital Case Medical Center of Cleveland, will present CytoCore's latest technological innovations in the diagnosis and treatment of cervical and endometrial cancers and related diseases.
Based on Dr. Gorodeski's groundbreaking work on the P2X7 molecule, a highly sensitive and accurate indicator of cancerous and pre-cancerous epithelial cells, CytoCore has developed the InPath(TM) System--a comprehensive suite of products to detect, diagnose and treat cervical cancer in women throughout the world. Clinical trials are presently underway for components of the InPath System--one is a marketing trial for a modification of the previously FDA-cleared e2 Collector(TM), a new non-invasive method of collecting cervical cell samples soon to be brought into production.
In addition, recent discoveries in the field of P2X7-related apoptosis of cervical cells enabled Dr. Gorodeski's research team to develop a novel approach to treat cancer epithelial cells. Collectively, these novel technologies licensed to CytoCore represent a unique end-to-end products system for the early detection and treatment of cervical and endometrial cancers, as well as other types of epithelial cancers. CytoCore has begun testing these products.
"CytoCore is uniquely positioned to bring to market a new range of cost-effective products with unique clinical capabilities designed to skillfully blend innovative science and established technology," said Dick Domanik, CytoCore's President.
The NYSAA Medical Equipment and Supplies Conference addresses the need for medical research and development investments brought by the increasing global demand for quality healthcare. During the conference, institutional investors and brokers will view presentations concerning new products and devices in oncology, cardiology, diabetes treatment, pain management, and orthopedics. For more information on the conference: http://www.nyssa.org/Template.cfm?Section=calendar&template=/ContentMa nagement/ContentDisplay.cfm&ContentID=10052 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About NYSSA
NYSSA promotes awareness and understanding of securities analysis, investing, and the operation of the securities markets. NYSSA was founded by a group that included Benjamin Graham, the "father of securities analysis" and one of the most influential men in the history of finance. With more than 9,000 members, NYSSA is the largest of the more than 134 financial analyst societies worldwide that comprise the CFA Institute (www.cfainstitute.org).
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com
Dr. Gorodeski has a significant financial interest in this research consisting of equity and fees as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore could generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland, and for CASE University.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Contact:
SIPR for CytoCore
Judy Curtis, + 1-650-274-1509
judy@sipr.com
or
Communications & Business Development Consultant
on behalf of CytoCore, Inc.
Gene Martineau,+ 1-212-348-1880
ebm@interport.net
--------------------------------------------------------------------------------
Source: CytoCore Inc.
NEWS
CytoCore Taps Dr. Richard Domanik as New President
Monday May 7, 12:55 pm ET
Industry Veteran to Accelerate CytoCore's Product Development and Commercialization
CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR - News), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, has appointed Richard Domanik, PhD, as its new president.
ADVERTISEMENT
Domanik, a thirty-year veteran of the regulated life sciences industry, will be responsible for the development and commercialization of CytoCore's products from the company's expanding technology base. He co-founded two developmental medical device technology companies and is familiar with the foundation work and science for CytoCore's innovative InPath(TM) System. He has extensive expertise in product development, specifically in bringing advanced technologies from the lab to market.
Domanik spent 15 years at Abbott Laboratories in a variety of roles including Laboratory Manager and Senior Systems Engineer, notably working with the multi-department advanced technologies group responsible for identifying and evaluating new technologies, developing them to the product prototype stage and supporting their development through to commercialization. He has been issued more than 20 patents for his innovative work and has been widely published in journals covering topics from biophysics and environmental chemistry to optical engineering. Domanik received his Ph.D. in biochemistry from Northwestern University.
"We are very pleased to have an individual of Dick's caliber take a leadership position in our company," said CytoCore's CEO, Dr. Augusto Ocana. "Dick's past experience, his expertise in product development -- and his knowledge of CytoCore's technology and product line -- make him well-suited to help bring our products from the lab to commercialization. With his guidance, we should be able to successfully expand our development activities for CytoCore's growing portfolio of products."
"I am excited to join the CytoCore team and to guide the development of CytoCore's innovative products based on the proprietary technologies and research of Dr. Gorodeski," said Domanik. "I am particularly attracted by CytoCore's focus on delivering to the market top-quality, cost-effective products with new clinical capabilities that blend innovative science and established technology. This next phase in CytoCore's growth is filled with promise and will be exciting."
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com
Dr. Gorodeski has a significant financial interest in this research consisting of equity and fees as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore could generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland, and for CASE University.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Contact:
on behalf of CytoCore, Inc.
Gene Martineau, +1-212-348-1880
Communications & Business Development Consultant
ebm@interport.net
or
SIPR for CytoCore
Judy Curtis, +1-650-274-1509
judy@sipr.com
--------------------------------------------------------------------------------
Source: CytoCore Inc.
The "z" according to bloomfield means "sold out of sequence"
Well, whatever they mean, I'm sticking to my guns.
I googled "market maker signals" and found this:
MARKET MAKER SIGNALS
Penny traders believe that Market Makers (MM) will "signal" moves in advance buy using small amounts of buys or sells as "signals". The "signals" are such a small amount of shares (worth no more than 5 or 10 dollars) that no trader would have paid a commission that costs more than the amount of shares bought. The "signals" are from one MM to another.
100 I need shares.
200 I need shares badly,but do not take the stock down.
300 Take the price down so I can load shares
400 Keep trading it sideways.
500 Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
Remeber this is a theory put forth by a lot of penny stock traders. This is not a guaranteed trading method so please use common sense and purchase stocks only after researching your investment thoroughly.
I don't get it. Good PRs are released and the pps goes down. Seems that way for all the stocks I hold.
Press Release Source: Viva World Trade
C.E.O. of Viva World Trade to Interview Live on MN1.Com
Friday April 13, 11:01 am ET
PUERTO VALLARTA, MEXICO--(MARKET WIRE)--Apr 13, 2007 -- Neil Mikkelsen, president and CEO of Viva World Trade, Inc. (Other OTC:VVWT.PK - News) will join Market News First in an exclusive interview Friday, April 13, 2007, at 1:30 p.m. CDT on www.mn1.com.
ADVERTISEMENT
Viva World Trade and its wholly owned subsidiary, Canmex Imports, the exclusive importer and national distributor of "mike's hard lemonade" in Mexico, have struck an agreement with one of the world's largest manufactures and distributors of hotel minibars and safe systems. The move will assist Viva World Trade in expanding and enhancing its presence and distribution across certain Mexico cities.
Mikkelsen will highlight what the move will do for the Company, what it expects to accomplish and how it has strategically positioned itself for success across the border.
To learn more about Viva World Trade, log on to www.mn1.com Friday, April 13, 2007.
About Viva World Trade, Inc.
Viva World Trade, Inc. is an importer and distributor of premium alcoholic beverages in Mexico. Viva and its Mexican subsidiary Canmex Imports are the exclusive importer and national distributor of the "mike's hard lemonade" brand family for the country of Mexico. "mike's hard lemonade" is one of North America's favorite and most successful flavored alcoholic beverages. The Company's shares are traded over-the-counter on the Pink Sheets - Trading Symbol: VVWT.
To learn more about Viva World Trade, Inc., visit www.vivaworldtrade.com
About MN1.com
Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.
Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.
Contact:
Investor Relations
Mercantile Ascendency
Thomas Collins
214-461-3500
tcollins@mercantileascendency.com
That's what I assumed, but there was someone here on this board (I remember him/her being a very popular poster)saying that MMs coordinated with each other and had certain codes and that 911 was sort of like an emergency meaning to keep the price at this level or don't let it go higher or something like that.
Someone on this board some time ago mentioned codes that the MMs have amongst each other - like 911. This person gave a description of several codes. Does anybody remember what these were?
I read on another board some time ago that the MMs have special codes amongst them and that 911 means "keep it here". I'm not sure if it's true but the poster is known to be a very reliable and knowledgeable person.
Unique Nature of P2X7 Cancer Biomarker Confirmed in Medical Literature
Thursday April 12, 3:44 pm ET
CytoCore's Focus on Early Cancer Detection Aligned with CDC and NCI
CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR - News), the late-stage bio-scientific research and medical device company for early detection and treatment of reproductive-tract cancers, today announced the results of an exhaustive literature search that has validated the unique status of the P2X7 biomarker in scientific literature.
ADVERTISEMENT
CytoCore commissioned an exhaustive literature search conducted by a major intellectual property law firm, which has yielded encouraging results. The search found nearly 1,000 references in peer-reviewed medical literature for this specific cancer biomarker subject area. None of these references identified any biomarkers that are expressed at measurable levels in both normal and precancerous cells, or that describe a biomarker that can track the progression of disease from the pre-cancerous stage to the invasive cancer stage. This was regardless of tissue types tested.
"We are greatly encouraged by the search findings. This solidifies the P2X7's unique status in terms of early detection of cancerous and precancerous cells. We are critically aware of the importance of early detection for reproductive cancers," said Dr. George Gorodeski, head of CytoCore's Scientific Research. "The assays we are developing are built around the P2X7's unique detection capabilities. We look forward to further testing and trials and FDA approval to solidify these assays for general use in screening for reproductive cancers."
Endometrial epithelial cancers contribute significantly to the morbidity and mortality of women: in the U.S. about 6 percent of all cancer deaths in women are caused by endometrial cancers. Major public health agencies such as FDA, NIH, NCI and CDC have identified early detection to be crucial in saving lives, as it provides greater treatment options while reducing medical costs.
"We believe that our focus on early cancer detection is in complete alignment with the current goals of our country's leading disease prevention institutions, such as the CDC and the NCI," CytoCore's CEO Dr. Augusto Ocana stated. "Not only does early detection save thousands of lives, but it can significantly decrease the financial burden on patient families, insurance companies and care providers. Our cancer screening assays underdevelopment, are based on the only known biomarker that identifies pre-cancerous or (pre-malignant) tissues. These assays need to go through successful trials and receive FDA approval. However, if approved, they have the potential to provide very early detection which in tern could provide a range of new treatment options."
For further information about CytoCore's full suite of products for the diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com. For further information about cervical cancer, visit the American Cancer Society's webpage: www.cancer.org.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com
Dr. George Gorodeski has a significant financial interest in this research consisting of equity and fees from the Company as a consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore may generate royalty income for Dr. Gorodeski, for University Hospital Case Medical Center of Cleveland and Case Western Reserve University.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Contact:
on behalf of CytoCore, Inc.
Gene Martineau, +1 212-348-1880
Communications & Business Development Consultant
ebm@interport.net
or
SIPR
Judy Curtis, +1 650-274-1509
judy@sipr.com
--------------------------------------------------------------------------------
Source: CytoCore Inc.
Press Release Source: CytoCore, Inc.
P2X7 Biomarker Identifies Cancerous and Pre-Cancerous Tissues
Thursday April 12, 2:55 pm ET
CytoCore to Confirm Biomarker's Early Detection Capability in Endometrial Cancer Trial
CHICAGO--(BUSINESS WIRE)--A third paper on the expanding research for CytoCore's unique P2X7 biomarker for the detection of endometrial cancers in women has been accepted for publication in the journal Gynecologic Oncology. The paper titled Decreased Expression of P2X7 in Endometrial Epithelial Pre-Cancerous and Cancer Cells will be available on the journal's web site in May 2007 and in the published version mid-summer.
ADVERTISEMENT
Written by a team directed by Dr. George Gorodeski, Director, Scientific-Medical Advisory Board, Chief Scientist and Lead Researcher of CytoCore, Inc. (OTCBB:CYCR - News), the latest findings open up expanded understanding of the role of the P2X7 biomarker in the development and detection of endometrial cancers in women. This research suggests that decreased expression of the P2X7 precedes cancer development in those tissues.
CytoCore's CEO, Dr. Augusto Ocana, stated, "Laboratory testing has shown the P2X7 is a unique marker able to identify uterine cancer, from early precancerous states through the later stages of malignancy. The marker's ability offers a very important new capability for the Uterine Cancer Screening assay that we currently have in trials. All major US Health organizations are prompting early detection of cancer as the key to saving lives and reducing spiraling costs associated with later stage treatments. Dr. Gorodeski's work with P2X7 continues to discover an expanding range of potent capabilities for this unique gene."
Data from Dr. Gorodeski's study suggest that the P2X7 biomarker has the capacity to identify uterine endometrial cancer cells and that P2X7, protein and mRNA assays could potentially be developed to screen for uterine endometrial pre-cancerous (pre-malignant) conditions. Another objective of the study, undertaken at University Hospital CASE Medical Center, was to better understand the cancer biology in cellular and molecular mechanisms that control expression of the P2X7 in epithelial cancer cells.
"The new results published in Gynecologic Oncology give important insight into the role of P2X7 in the development of endometrial uterine cancer, which could also be applied to the early detection of cervical and bladder pre-cancerous tissues," said Dr. Gorodeski. "Because of its presence in epithelial cells throughout the body, the P2X7 is potentially a biomarker with the unique capability to differentiate pre-cancerous conditions in other epithelial tissues not yet tested."
CytoCore anticipates further scientific developments and announcements in the next two quarters from Dr. Gorodeski's ongoing research into the P2X7's unique capabilities.
For further information about CytoCore's full suite of products for the diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com. For further information about cervical cancer, visit the American Cancer Society's webpage: www.cancer.org.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com
Dr. George Gorodeski (MD, PhD, Professor at University Hospital Case Medical Center of Cleveland and Case Western Reserve University) has a significant financial interest in this research consisting of equity and fees from the Company as a consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore may generate royalty income for Dr. Gorodeski, for University Hospital Case Medical Center of Cleveland and Case Western Reserve University.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Contact:
on behalf of CytoCore, Inc.
Gene Martineau, +1-212-348-1880
Communications & Business Development Consultant
ebm@interport.net
or
SIPR
Judy Curtis, +1-650-274-1509
judy@sipr.com
--------------------------------------------------------------------------------
Source: CytoCore, Inc.
NEWS!!!!!!
Viva World Trade Approved for Listing With Mexico's 2nd Largest Supermarket Retailer
Wednesday April 11, 11:44 am ET
PUERTO VALLARTA, MEXICO--(MARKET WIRE)--Apr 11, 2007 -- Viva World Trade, Inc. (Other OTC:VVWT.PK - News) (the "Company" or "Viva") and its Mexican subsidiary Canmex Imports ("Canmex"), the exclusive importer and national distributor of the "mike's hard lemonade" brand family in Mexico, are pleased to announce the Company has been approved for listing "mike's" products with nationwide retailer Organizacion Soriana, Mexico's second largest supermarket chain.
ADVERTISEMENT
Soriana was founded in 1905 and has been listed on the Mexican Stock Exchange since 1987. They own and operate 235 modern supermarket stores and 80 convenience stores. Soriana is rapidly expanding its store base and has pledged to invest over $700 million to open 60 more supermarket stores over the next year. Soriana is the second largest Mexican supermarket chain, surpassed nationwide only by Walmart.
Through an exclusive arrangement with strategic sales and marketing partner TVK Latin America, a successful Mexico City-based importer and distributor of alcoholic beverages, Viva has gained access to the Soriana retail network alongside other successful TVK product offerings. Soriana currently retails TVK distributed alcoholic beverages across Mexico. Initial orders on a regional level are expected to begin later this month, with potential distribution to all Soriana stores by the end of the year.
"This sales opportunity with Soriana will be another major step forward for Viva and 'mike's' in Mexico. Their modern stores, nationwide presence, and aggressive expansion plans make Soriana a perfect retail partner as we develop the 'mike's' brand and expand our product offerings in the coming months," said Neil Mikkelsen, President & CEO.
About Viva World Trade, Inc.
Viva World Trade, Inc. is an importer and distributor of premium alcoholic beverages in Mexico. Viva and its Mexican subsidiary Canmex Imports are the exclusive importer and national distributor of the "mike's hard lemonade" brand family for the country of Mexico. "mike's hard lemonade" is one of North America's favorite and most successful flavored alcoholic beverages. The Company's shares are traded over-the-counter on the Pink Sheets - Trading Symbol: VVWT.
You sniper you!!!!!!! Great job.
I think I'll have to open a new account. My Schwab account is my 401K rollover IRA I'm playing with. I never intended to play with it but when I invested 11K 3 years ago into a penny stock that's now worth 135K, I figured a little bit here and there won't hurt. The only thing is, I can't touch it till I retire.
My thoughts exactly.
Just placed an order for 999,999 at ask (that's as high as Schwab will let me at one time). Originally bid .001 but thought maybe I wouldn't get it filled so I changed it to .0011. Heck what's $100 when there's potential of making so much more. I hope I found a good one here. 999,999 sucks - I wanted a nice round number.
Diana
One I won't forget. Sorry.
Thanks.
So I've been told. I hope it gets deleted. I've only been reading these message boards for a few weeks. I'll just stick to that - reading and not posting.
Hasher, please delete.
Checked it out. Do they just change the names to correspond with actual posters of today? I should have done my research. Sorry.
Early this am the bid was .81 and ask was .88. Stayed that way for a long time then the bid started going up. Nobody wants to give this baby up.
Diana
My first cousin was cremated then his urn was buried just this past Saturday. He was a devout catholic and the priest held a service at the cemetery. I was told that cremation was allowed as long as the ashes were buried.
Diana
You can check out level 2's for free at:
http://www.bloomfieldinvestmentclub.com